Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 29 | 2021 | 40 | 9.340 |
Why?
|
| Antiviral Agents | 32 | 2021 | 70 | 8.110 |
Why?
|
| Hepatitis C | 20 | 2022 | 43 | 6.930 |
Why?
|
| Liver Diseases | 14 | 2022 | 31 | 6.110 |
Why?
|
| Hepacivirus | 23 | 2022 | 33 | 4.730 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 47 | 3.970 |
Why?
|
| Liver Transplantation | 9 | 2023 | 65 | 3.960 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 5 | 2.190 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 10 | 1.920 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 42 | 1.870 |
Why?
|
| Pregnancy | 13 | 2022 | 306 | 1.750 |
Why?
|
| Ribavirin | 9 | 2016 | 10 | 1.700 |
Why?
|
| Humans | 71 | 2024 | 25969 | 1.670 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 7 | 1.540 |
Why?
|
| Coinfection | 4 | 2023 | 21 | 1.320 |
Why?
|
| Sulfonamides | 7 | 2020 | 37 | 1.250 |
Why?
|
| Hepatitis B | 5 | 2019 | 12 | 1.220 |
Why?
|
| United States | 19 | 2022 | 1972 | 1.210 |
Why?
|
| Interferon-alpha | 5 | 2012 | 30 | 1.210 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 91 | 1.190 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 44 | 1.190 |
Why?
|
| HIV Infections | 4 | 2021 | 463 | 1.170 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 18 | 1.160 |
Why?
|
| Female | 37 | 2024 | 14351 | 1.120 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 4 | 1.070 |
Why?
|
| Societies, Medical | 3 | 2022 | 146 | 0.990 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.970 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.910 |
Why?
|
| Drug Therapy, Combination | 13 | 2021 | 170 | 0.910 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.880 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3293 | 0.860 |
Why?
|
| Gastroenterology | 3 | 2017 | 6 | 0.800 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 39 | 0.790 |
Why?
|
| Living Donors | 1 | 2021 | 7 | 0.760 |
Why?
|
| Prejudice | 1 | 2021 | 31 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 104 | 0.710 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 20 | 0.710 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 21 | 0.700 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 38 | 0.700 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.700 |
Why?
|
| Patient Selection | 1 | 2021 | 193 | 0.690 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 120 | 0.680 |
Why?
|
| Genotype | 10 | 2017 | 335 | 0.680 |
Why?
|
| Adult | 21 | 2021 | 7351 | 0.650 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.650 |
Why?
|
| Viral Load | 5 | 2016 | 71 | 0.640 |
Why?
|
| Obesity | 1 | 2021 | 276 | 0.630 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.630 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.630 |
Why?
|
| Algorithms | 2 | 2020 | 358 | 0.620 |
Why?
|
| Fear | 1 | 2018 | 43 | 0.600 |
Why?
|
| Liver | 3 | 2022 | 123 | 0.600 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.600 |
Why?
|
| Middle Aged | 21 | 2021 | 8508 | 0.570 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.540 |
Why?
|
| Cyclopropanes | 5 | 2020 | 14 | 0.540 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.530 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 11 | 0.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 1 | 0.530 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.520 |
Why?
|
| Virology | 1 | 2015 | 2 | 0.520 |
Why?
|
| Young Adult | 9 | 2021 | 1848 | 0.480 |
Why?
|
| Length of Stay | 2 | 2016 | 301 | 0.480 |
Why?
|
| Liver Function Tests | 3 | 2022 | 19 | 0.470 |
Why?
|
| Patient Readmission | 1 | 2016 | 130 | 0.470 |
Why?
|
| Male | 23 | 2021 | 13984 | 0.460 |
Why?
|
| Heart Failure | 1 | 2016 | 167 | 0.450 |
Why?
|
| Mass Screening | 5 | 2021 | 166 | 0.450 |
Why?
|
| Prevalence | 3 | 2023 | 433 | 0.440 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 447 | 0.440 |
Why?
|
| Risk Factors | 6 | 2023 | 2240 | 0.440 |
Why?
|
| Prognosis | 5 | 2022 | 749 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2013 | 15 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2013 | 22 | 0.430 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 32 | 0.430 |
Why?
|
| Health Policy | 1 | 2013 | 49 | 0.420 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3291 | 0.420 |
Why?
|
| Disease Management | 2 | 2016 | 108 | 0.400 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.390 |
Why?
|
| Proline | 4 | 2019 | 10 | 0.360 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 5 | 0.360 |
Why?
|
| Imidazoles | 4 | 2020 | 55 | 0.360 |
Why?
|
| RNA, Viral | 4 | 2022 | 44 | 0.360 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 199 | 0.350 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.350 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 16 | 0.340 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 14 | 0.340 |
Why?
|
| Aged | 14 | 2020 | 8704 | 0.330 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 156 | 0.310 |
Why?
|
| Cost of Illness | 2 | 2023 | 45 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 3 | 0.300 |
Why?
|
| Motivation | 3 | 2023 | 92 | 0.300 |
Why?
|
| Cohort Studies | 6 | 2021 | 1815 | 0.290 |
Why?
|
| Fatty Liver | 2 | 2019 | 21 | 0.290 |
Why?
|
| Anemia | 1 | 2008 | 92 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2019 | 68 | 0.280 |
Why?
|
| Adolescent | 4 | 2020 | 2062 | 0.260 |
Why?
|
| Benzofurans | 3 | 2020 | 6 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 63 | 0.250 |
Why?
|
| Valine | 4 | 2019 | 6 | 0.240 |
Why?
|
| Drug Interactions | 2 | 2015 | 35 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 706 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 122 | 0.230 |
Why?
|
| Risk Assessment | 3 | 2018 | 621 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2019 | 1646 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.220 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 2 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 6 | 0.220 |
Why?
|
| Amides | 2 | 2020 | 16 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 15 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 29 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 416 | 0.210 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.210 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.210 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 6 | 0.210 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 4 | 0.210 |
Why?
|
| RNA | 1 | 2022 | 33 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 26 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 4661 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2022 | 45 | 0.200 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 92 | 0.190 |
Why?
|
| Fertility | 1 | 2021 | 17 | 0.190 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.190 |
Why?
|
| Leucine | 2 | 2018 | 11 | 0.190 |
Why?
|
| World Health Organization | 1 | 2020 | 11 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 76 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 9 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 126 | 0.180 |
Why?
|
| Pandemics | 1 | 2022 | 238 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 190 | 0.180 |
Why?
|
| Anilides | 2 | 2019 | 6 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 306 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 75 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 83 | 0.170 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 91 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 22 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 60 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 288 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1710 | 0.160 |
Why?
|
| Logistic Models | 2 | 2010 | 360 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 23 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2019 | 538 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 315 | 0.150 |
Why?
|
| Time Factors | 3 | 2016 | 1361 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 21 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 225 | 0.140 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 49 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 929 | 0.140 |
Why?
|
| Drug Approval | 1 | 2016 | 7 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1066 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 12 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 27 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 49 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 39 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 290 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 8 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 7 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 129 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 30 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 11 | 0.130 |
Why?
|
| Benchmarking | 1 | 2015 | 35 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2015 | 100 | 0.130 |
Why?
|
| Benzazepines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 11 | 0.120 |
Why?
|
| Comorbidity | 4 | 2018 | 466 | 0.120 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 151 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 34 | 0.120 |
Why?
|
| Liver Failure | 1 | 2015 | 8 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 148 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 35 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 289 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 304 | 0.120 |
Why?
|
| Hospitalists | 1 | 2014 | 5 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 293 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 73 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 69 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 206 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2013 | 9 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 11 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 5 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 120 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 34 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 33 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 457 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 109 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 6 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 20 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 104 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 122 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 259 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 485 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 215 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2008 | 74 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 853 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 62 | 0.060 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 1 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 1 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 7 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 22 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 32 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 10 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 55 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 15 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 29 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 163 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 171 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 18 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 609 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 42 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 95 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 48 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 126 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 6 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 29 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 29 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 137 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 29 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 36 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 670 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 130 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 132 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 141 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 117 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 64 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 161 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 324 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 211 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 238 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 321 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 60 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 45 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 132 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 685 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 29 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 37 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 85 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 122 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 862 | 0.020 |
Why?
|